Want to see PURE full AI Analyst Report?
PURE Stock Chart & Stats
$0.07
>-$0.01(-8.90%)
At close: 4:00 PM EDT
$0.07
>-$0.01(-8.90%)
Day’s Range― - ―
52-Week Range$0.04 - $0.11
Previous CloseN/A
Volume1.60K
Average Volume (3M)53.72K
Market Cap
$11.70M
Enterprise Value$13.10
Total Cash (Recent Filing)$983.00K
Total Debt (Recent Filing)$6.50M
Price to Earnings (P/E)―
Beta-0.62
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding130,017,580
10 Day Avg. Volume24,352
30 Day Avg. Volume53,720
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-1.96
Price to Sales (P/S)4.56
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue ReboundThe substantial TTM sales rebound indicates renewed demand for the company’s sanitation products and provides a larger commercial base from which operating leverage could develop if growth continues.
Proprietary Antimicrobial TechnologyA proprietary silver-based antimicrobial platform gives Pure Bioscience a differentiated product foundation and may support customer retention, product extensions, and broader adoption in sanitation-focused commercial markets.
Focused Commercial Sanitation MarketConcentration on food-related and institutional sanitation creates a defined need-based market rather than relying only on discretionary consumer demand. Recurring sanitation requirements can support repeat product usage when distribution improves.
Bears Say
Persistent UnprofitabilityOngoing operating and net losses show that revenue growth has not yet translated into a self-sustaining earnings model. Continued negative margins could constrain reinvestment, weaken financing access, and delay the benefits of scale.
Fragile Balance SheetNegative equity reflects accumulated losses and leaves limited financial flexibility. Combined with a small asset base and meaningful debt, this structure increases solvency and refinancing risk if operating losses continue.
Ongoing Cash Burn And Reporting UncertaintyPersistent negative operating and free cash flow means the core business is not funding operations, increasing reliance on external capital. Volatile and apparently inconsistent reported figures also reduce confidence in assessing sustainable cash generation.
Pure Bioscience News
PURE FAQ
What was Pure Bioscience’s price range in the past 12 months?
Pure Bioscience lowest stock price was $0.04 and its highest was $0.11 in the past 12 months.
What is Pure Bioscience’s market cap?
Pure Bioscience’s market cap is $11.70M.
When is Pure Bioscience’s upcoming earnings report date?
Pure Bioscience’s upcoming earnings report date is Nov 03, 2026 which is in 65 days.
How were Pure Bioscience’s earnings last quarter?
Pure Bioscience released its earnings results on Jun 15, 2026. The company reported -$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Pure Bioscience overvalued?
According to Wall Street analysts Pure Bioscience’s price is currently Overvalued.
Does Pure Bioscience pay dividends?
Pure Bioscience does not currently pay dividends.
What is Pure Bioscience’s EPS estimate?
Pure Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pure Bioscience have?
Pure Bioscience has 130,017,580 shares outstanding.
What happened to Pure Bioscience’s price movement after its last earnings report?
Pure Bioscience reported an EPS of -$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.857%.
Which hedge fund is a major shareholder of Pure Bioscience?
Currently, no hedge funds are holding shares in PURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pure Bioscience
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a ready-to-use hard surface disinfectant and food contact surface sanitizer and disinfectant; PURE Control, eliminates pathogens in produce, such as salmonella, e. coli, and listeria; PURE Multi-Purpose Hi-Foam Floor Cleaner Concentrate, a cleaning product for stainless steel, floors, walls, and painted areas; PURE Multi-Purpose Floor Cleaner, for sanitation in food processing plants, commercial kitchens, healthcare facilities, schools, and hospitality settings; and SILVERION, a SDC-based antimicrobial formulation for use as a raw material ingredient in the manufacturing of personal care products. The company serves food processing, food service and hospitality, healthcare, facility care, transportation, and personal care industries. It sells its products through end-use customers and third-party distributors. The company was incorporated in 1992 and is based in El Cajon, California.
Technical Analysis
Mannatech
―
United-Guardian
―
Tantech Holdings
―
Grove Collaborative Holdings
―
Yoshitsu Co. Ltd. Sponsored ADR
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.62% Other Institutional Investors
99.38% Public Companies and
Individual Investors